Ferriscan receives FDA approval

Inner Vision Biometrics (IVB), a subsidiary of Perth based Resonance Health (ASX: RHT) has received FDA marketing approval for its novel diagnostic test for liver iron concentrations.

The FerriScan test non-invasively measures the iron content of the liver, and can be used to detect and treat iron overload disorders including thalassemia and hereditary haemochromatosis using specifically configured MRI machines. Scan data is analysed at a centralised IVB image processing centre using proprietary software.

FerriScan has already been approved for listing by the TGA and has received CE Mark approval in Europe, where partnerships with diagnostic imaging companies are already in place.

"We will be meeting with major US-based diagnostic imaging groups over the next several weeks to accelerate arrangements for the US commercial launch of the FerriScan test," said Resonance's executive director Tony Fitzgerald.